BUSINESSBLOOMBERG
Dr. Reddy’s Sees Weight-Loss Drug Boosting Growth After Setback
Dr. Reddy’s Laboratories expects its generic anti-obesity drug to boost growth in the six months through March after resolving an impurity issue with the key ingredient and resuming supply in early November.
Related Signal
Adjacent reporting
- Dr Reddy’s runs into trouble with its weight-loss drug
- Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
- India Fat-Loss Drug Sales Slow After Early Spike From Generics
- New weight-loss drug Retatrutide showing stronger results than current options
- Weight loss without muscle loss? The next generation of drugs is testing the idea
- Weight loss drug maker sinks 25% after new safety data spooks investors